Boston Scientific introduces new WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device to lower the risk of stroke in patients with Non-valvular Atrial Fibrillation (NVAF).
The device developed with newest stroke reduction technology enables further advanced procedures by providing safe treatment options for a wide range of patients with non-valvular atrial fibrillation. The device eliminates the need for patients with an alternative approach to oral anticoagulation therapy by closing the left atrial appendage permanently the area of the heart where blood clots resulting in stroke.
WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device consists of fully rounded design offering physicians the ability to safely enter, and maneuver within, the left atrial appendage. The device with new technology can be fully recaptured, repositioned and redeployed for precise placement. The device available in broader size options compared to the previous generation device treats a wider range of patient’s anatomies.
US Food and Drug Administration (FDA) has approved WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device to reduce the risk of stroke in people with non-valvular AF.